Skip to main content

Table 6 Details and outcomes of 6 HBsAg-negative/HBcAb-positive DLBCL patients who developed HBV reactivation after rituximab-containing chemotherapy

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Patient no.

Age (years)

Sex

Baseline

R-CHOP cycles

Interval between last cycle and HBV reactivation (days)

At diagnosis of HBV reactivation

Outcome

IPI

Stage

HBeAb

ALT (U/L)

AST (U/L)

TB (μmol/L)

Peak HBV DNA (IU/mL)

Peak ALT (U/L)

Peak AST (U/L)

Peak TB (μmol/L)

1

65

Male

4

3

+

18.0

68.2

8.9

5

42

1.72 × 107

333.1

285.8

69.0

Alive and well

2

21

Male

3

3

-

22.0

27.0

36.6

2

24

8.60 × 103

107.6

60.2

47.1

Died of lymphoma

3

69

Female

2

3

-

21.0

25.0

9.4

6

23

1.80 × 105

230.8

120.1

11.0

Alive and well

4

70

Male

3

3

-

10.0

29.0

11.1

7

98

4.76 × 106

239.0

174.0

8.1

Died of lymphoma

5

26

Female

2

3

+

10.0

15.0

6.4

2

27

9.28 × 106

106.0

89.0

7.8

Alive and well

6

68

Male

1

1

-

25.0

35.0

7.0

6

29

4.47 × 104

219.2

204.5

11.3

Alive and well

  1. R-CHOP, cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine, and prednisone regimen. Other abbreviations as in Tables 1 and 2.